Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Chih-Wei Lin

Showing results (101-110 of 115) with videos related to

Pageof 12
Sort By:
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|July 18, 2018
Efficacy and Pharmacokinetics of Glecaprevir and Pibrentasvir With Concurrent Use of Acid-Reducing Agents in Patients With Chronic HCV InfectionSteven Flamm, K Rajender Reddy, Neddie Zadeikis, et al.
Proceedings of the National Academy of Sciences of the United States of America|July 11, 2018
Fully human agonist antibodies to TrkB using autocrine cell-based selection from a combinatorial antibody librarySpyros Merkouris, Yves-Alain Barde, Kate E Binley, et al.
Plos Pathogens|March 22, 2021
A cross-neutralizing antibody between HIV-1 and influenza virusChang-Chun D Lee, Yasunori Watanabe, Nicholas C Wu, et al.
Hepatology (Baltimore, Md.)|January 28, 2017
Glecaprevir and pibrentasvir for 12 weeks for hepatitis C virus genotype 1 infection and prior direct-acting antiviral treatmentFred Poordad, Franco Felizarta, Armen Asatryan, et al.
Hepatology (Baltimore, Md.)|September 20, 2017
Glecaprevir/pibrentasvir for hepatitis C virus genotype 3 patients with cirrhosis and/or prior treatment experience: A partially randomized phase 3 clinical trialDavid Wyles, Fred Poordad, Stanley Wang, et al.
The Lancet. Infectious Diseases|August 19, 2017
Glecaprevir plus pibrentasvir for chronic hepatitis C virus genotype 1, 2, 4, 5, or 6 infection in adults with compensated cirrhosis (EXPEDITION-1): a single-arm, open-label, multicentre phase 3 trialXavier Forns, Samuel S Lee, Joaquin Valdes, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|March 30, 2019
Safety and Pharmacokinetics of Glecaprevir/Pibrentasvir in Adults With Chronic Genotype 1-6 Hepatitis C Virus Infections and Compensated Liver DiseaseEdward Gane, Fred Poordad, Neddie Zadeikis, et al.
Thrombosis Research|February 8, 2023
Plasma riboflavin fluorescence as a diagnostic marker of mesenteric ischemia-reperfusion injury in ratsXueqin Wu, Lun-Zhang Guo, Yi-Hung Liu, et al.
ACS Chemical Biology|January 21, 2017
An Effective Bacterial Fucosidase for Glycoprotein RemodelingTsung-I Tsai, Shiou-Ting Li, Chiu-Ping Liu, et al.
Hepatology (Baltimore, Md.)|June 30, 2019
Pharmacokinetics, Safety, and Efficacy of Glecaprevir/Pibrentasvir in Adolescents With Chronic Hepatitis C Virus: Part 1 of the DORA StudyMaureen M Jonas, Robert H Squires, Susan M Rhee, et al.
Pageof 12

Showing results (101-110 of 115) with videos related to

Sort By:
Pageof 12
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|July 18, 2018
Efficacy and Pharmacokinetics of Glecaprevir and Pibrentasvir With Concurrent Use of Acid-Reducing Agents in Patients With Chronic HCV InfectionSteven Flamm, K Rajender Reddy, Neddie Zadeikis, et al.
Proceedings of the National Academy of Sciences of the United States of America|July 11, 2018
Fully human agonist antibodies to TrkB using autocrine cell-based selection from a combinatorial antibody librarySpyros Merkouris, Yves-Alain Barde, Kate E Binley, et al.
Plos Pathogens|March 22, 2021
A cross-neutralizing antibody between HIV-1 and influenza virusChang-Chun D Lee, Yasunori Watanabe, Nicholas C Wu, et al.
Hepatology (Baltimore, Md.)|January 28, 2017
Glecaprevir and pibrentasvir for 12 weeks for hepatitis C virus genotype 1 infection and prior direct-acting antiviral treatmentFred Poordad, Franco Felizarta, Armen Asatryan, et al.
Hepatology (Baltimore, Md.)|September 20, 2017
Glecaprevir/pibrentasvir for hepatitis C virus genotype 3 patients with cirrhosis and/or prior treatment experience: A partially randomized phase 3 clinical trialDavid Wyles, Fred Poordad, Stanley Wang, et al.
The Lancet. Infectious Diseases|August 19, 2017
Glecaprevir plus pibrentasvir for chronic hepatitis C virus genotype 1, 2, 4, 5, or 6 infection in adults with compensated cirrhosis (EXPEDITION-1): a single-arm, open-label, multicentre phase 3 trialXavier Forns, Samuel S Lee, Joaquin Valdes, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|March 30, 2019
Safety and Pharmacokinetics of Glecaprevir/Pibrentasvir in Adults With Chronic Genotype 1-6 Hepatitis C Virus Infections and Compensated Liver DiseaseEdward Gane, Fred Poordad, Neddie Zadeikis, et al.
Thrombosis Research|February 8, 2023
Plasma riboflavin fluorescence as a diagnostic marker of mesenteric ischemia-reperfusion injury in ratsXueqin Wu, Lun-Zhang Guo, Yi-Hung Liu, et al.
ACS Chemical Biology|January 21, 2017
An Effective Bacterial Fucosidase for Glycoprotein RemodelingTsung-I Tsai, Shiou-Ting Li, Chiu-Ping Liu, et al.
Hepatology (Baltimore, Md.)|June 30, 2019
Pharmacokinetics, Safety, and Efficacy of Glecaprevir/Pibrentasvir in Adolescents With Chronic Hepatitis C Virus: Part 1 of the DORA StudyMaureen M Jonas, Robert H Squires, Susan M Rhee, et al.
Pageof 12